- Home
- IMUX vs RCON Comparison
IMUX vs RCON Comparison
Compare IMUX & RCON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- RCON
- Stock Information
- Founded
- IMUX 2016
- RCON 2007
- Country
- IMUX United States
- RCON China
- Employees
- IMUX N/A
- RCON N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- RCON Oilfield Services/Equipment
- Sector
- IMUX Health Care
- RCON Energy
- Exchange
- IMUX Nasdaq
- RCON Nasdaq
- Market Cap
- IMUX 90.4M
- RCON 86.1M
- IPO Year
- IMUX N/A
- RCON 2009
- Fundamental
- Price
- IMUX $0.79
- RCON $2.21
- Analyst Decision
- IMUX Strong Buy
- RCON
- Analyst Count
- IMUX 5
- RCON 0
- Target Price
- IMUX $7.50
- RCON N/A
- AVG Volume (30 Days)
- IMUX 1.3M
- RCON 70.9K
- Earning Date
- IMUX 11-06-2025
- RCON 09-26-2025
- Dividend Yield
- IMUX N/A
- RCON N/A
- EPS Growth
- IMUX N/A
- RCON N/A
- EPS
- IMUX N/A
- RCON N/A
- Revenue
- IMUX N/A
- RCON $8,996,572.00
- Revenue This Year
- IMUX N/A
- RCON N/A
- Revenue Next Year
- IMUX N/A
- RCON $12.17
- P/E Ratio
- IMUX N/A
- RCON N/A
- Revenue Growth
- IMUX N/A
- RCON N/A
- 52 Week Low
- IMUX $0.56
- RCON $1.40
- 52 Week High
- IMUX $2.11
- RCON $7.16
- Technical
- Relative Strength Index (RSI)
- IMUX 42.07
- RCON 47.07
- Support Level
- IMUX $0.74
- RCON $1.87
- Resistance Level
- IMUX $0.90
- RCON $2.13
- Average True Range (ATR)
- IMUX 0.06
- RCON 0.24
- MACD
- IMUX -0.00
- RCON 0.01
- Stochastic Oscillator
- IMUX 25.02
- RCON 33.02
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About RCON Recon Technology Ltd.
Recon Technology Ltd is an oilfield service company. The company is engaged in providing oilfield automation products, specialized equipment for oil and gas production and transportation, chemicals, and field services to petroleum companies mainly in the People's Republic of China (PRC). It has four reportable operating segments: Automation Product and Software, Equipment and Accessories, Platform outsourcing services, and Oilfield Environmental Protection. The majority of the firm's revenue comes from the Automation Product and Software segment which provides products and services like pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system among others.